Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
varicella vaccine (live) (Research Foundation for Microbial Diseases of Osaka University)
- Development stage
- Unknown
- Lead developer
- Research Foundation for Microbial Diseases of Osaka University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
The Oka/Biken live attenuated varicella vaccine is a viral vaccine developed by The Research Foundation for Microbial Diseases of Osaka University (BIKEN) for the prevention of varicella (chickenpox). It is based on the Oka strain of the varicella-zoster virus (VZV), which was originally isolated and attenuated by Dr. Michiaki Takahashi at Osaka University in the 1970s. The vaccine works by inducing both humoral (antibody) and cell-mediated immune responses against VZV, providing long-term protection against chickenpox. It is typically administered as a subcutaneous injection and is widely used in Japan and other regions, serving as the parent strain for most varicella vaccines used worldwide, including those produced by Merck and GSK.
- Brand names
- Varicella Vaccine BikenVaricella Vaccine GC Biken
- Other names
- Oka/Biken live attenuated varicella vaccineOka strain varicella vaccinefreeze-dried live attenuated varicella vaccine (BIKEN)
Beyond the preview
Go deeper on varicella vaccine (live) (Research Foundation for Microbial Diseases of Osaka University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on varicella vaccine (live) (Research Foundation for Microbial Diseases of Osaka University).